IFNB1 and Alzheimer disease: Of note, in a rat model of AD, IFN-β treatment improved memory and reduced inflammatory markers (190), and in humans with subtle cognitive decline, a preclinical feature of AD, reduced blood IFN-I signaling levels is linked to an increased risk of progression to mild cognitive impairment (189).